Posts tagged proof-of-concept
In conversation with Hrishikesh Suresh of NeuroGate

As CEO and one of three co-founders of upstart NeuroGate, Hrishikesh Suresh currently is completing his final year as a medical student at McMaster University in Hamilton, Ontario and plans to pursue a six-year residency in neurosurgery. But since the age of 12, he has had a passion for computer coding and, as a result, contributed to the company’s software development, which aims to capture motion data as a method to diagnose neurodegenerative diseases...

Read More
PureTech targeting dysfunctions in brain, gut, immune system

With eight clinical-stage studies underway, including two pivotal trials expected to readout later this year, PureTech Health (LSE:PRTC) is taking a novel approach to drug development, targeting serious diseases caused by dysfunctions in the brain, gut and immune system.

Read More
FeatureLeonard Zehrclinical study, clinical-stage, pivotal trial, PureTech, PureTech Health, LSE:PRTC, drug, drug development, diseases, chronic diseases, Bharatt Chowrira, Drs Chowrira, disease progression, slowing disease, halting disease, reversing disease, chronic, chronic disease, slow disease progression, detection, chronic disease treatment, biopharma, biopharmaceutical company, innovative approach, GI, gastrointestinal, obesity, bariatric surgery, Pharmaceuticals, obese, oral, oral therapy, oral therapies, GI tract, gastrointestinal tract, Gelesis100, Gelesis, transformative, transformative treatment, medical device, drug absorption, nutrient absorption, body weight loss, overweight, prediabetes, type 2 diabetes, obesity related diseases, fatty liver disease, osteoarthritis, cardiovascular, cardiovascular disease, non-alcoholic fatty liver disease, diabetes, diabetes therapy, Gelesis200, Gelesis 200, Gelesis 100, glycemic, glycemic control, liver disease, liver, proof-of-concept, preclinical, immune, aging population, innovation investment, immunosenescence, aging immune system, respiratory tract infections, pneumonia, influenza, mTOR, mTORC1, immune-enhance, Phase 2, peer-reviewed studies, RTB 101, cold, flu, Akili, ADHD, Attention Deficit Hyperactivity Disorder, Project:EVO, Alzheimer’s, Alzheimer's disease, Pfizer, digital medicine platform, cognitive science, Adam Gazzaley, Dr. Adam Gazzaley, UCSF, Dr. Gazzaley, elderly, elder patients, ADHD treatment, Internation Conference on Clinical Trails for Alzheimer's disease, pipeline, LSE, PRTC
Tetra Bio-Pharma sets active cannabis clinical programs

Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) has an aggressive clinical trial program set to begin in the final quarter this year and first quarter of 2018 to prove the efficacy and safety of at least three therapeutic cannabis products.

Read More
FeatureLeonard ZehrTetra, Tetra Bio-Pharma, OTCQB, OTCQB:TBPMF, TBPMF, CSE, CSE:TBP, TBP, clinical trial, therapeutic cannabis products, cannabis, cannabis products, natural health cannabis, natural health, Andre Rancourt, topical treatment, pain management, cardiovascular disease, athletic performance, skin care, topical cream, sales and marketing, branding, distribution, Phyto Pain Pharma, cannabis-based drug products, Agro Tek, Grow Pros, marijuana, recreational marijuana company, global leader, nutraceuticals, toxic, toxic side effects, steroids, Health Canada, FDA, insurance companies, PPP001, smokeable marijuana, advanced cancer pain, cancer pain, cancer, pellet, titanium inhalation device, digital readout, consumption, Aphria, OTCQB:APHQF, APHQF, TSX, TSX:APH, APH, licensed producer, active pharmaceutical ingredient, Phase 1 study, safety data, pharmacokinetic data, tetrahydrocannabinol, THC, pain relief, cancer patients, Phase 1 trial, Phase 3 clinical trial, chemical entity, pivotal trial, Notice of Compliance, ACMPR, opioids, severe pain, IntelGenx, OTCQX, OTCQX:IGXT, IGXT, TSXV, TSXV:IGX, IGX, oral mucoadhesive, dronabinol XL tablet, cheek, AdVersa controlled-release technology, THC tablet, synthetic THC, North American patients, anorexia, cancer chemotherapy-related pain, chemotherapy-related pain, PPP002, Phase 2 trial, Division of Anesthesia, Analgesia, Addiction Products, and Addiction Products, 505(b)(2) regulatory filing, 505(b)(2), regulatory filing, Dronabinol XL AdVersa Mucoadhesive tablet, dry eye disorder, ocular pain, inflammation, Panag Pharma, proof-of-concept, cannabinoid eye drop, eye drop, PPP003, exema, general neuropathic pain, business model, pharmaceutical relevance
Vyome completing enrollment in acne POC trial

Closely-held Vyome Biosciences expects to enroll the final patient next month in a proof-of-concept clinical trial in the U.S. of its lead molecule for drug-resistant acne, VB 1953.

Read More
Histogenics to complete Phase 3 enrollment in Q2

Histogenics (NASDAQ:HSGX) expects to complete enrollment by the end of the second quarter this year in a Phase 3 clinical trial of its NeoCart biologic cell therapy and tissue engineering solution for knee cartilage regeneration.

Read More
Jaguar, Napo merger set for transformative growth

The proposed merger of Jaguar Animal Health (NASDAQ:JAGX) and closely-held Napo Pharmaceuticals is expected to create a combined company with prescription product revenue, potential line extensions and an expanded pipeline.

Read More
IntelGenx sees 2017 milestones as transformational

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has multiple milestones on tap this year with its oral film drug delivery platform, VersaFilm, as it continues building strategic partnerships in the pharmaceutical industry.

Read More
Pivot Pharma seeks financing to develop drugs for women’s cancers

Upstart Pivot Pharmaceuticals (OTCQB:PVOTF), which was launched in the fourth quarter last year, is in talks with investors to raise up to $8-million in 2016 to initiate proof-of-concept studies for one of its two lead drug candidates for the treatment of endometrial and triple-negative breast cancers.

“These women’s cancers represent areas of high unmet medical need due to genomic mutations and our focus is to develop fast-to-market novel drugs that can be used in combination with other anticancer drugs,” CEO, Pravin Chaturvedi, says in an interview with BioTuesdays.com.

Funds raised this year also will be used to expand the company’s business development programs, including plans to acquire additional later-stage drug candidates for the treatment of women’s health.

Read More
In conversation with Geoffrey Hamilton-Fairley

As CEO of closely-held Oncimmune, an early cancer diagnostic company in Britain, Geoffrey Hamilton-Fairley has had a personal commitment to cancer detection. His father was the first medical oncologist in the UK and an original adopter of chemotherapy. Early on, Mr. Hamilton-Fairley chose a different career path, even though he obtained an Honors degree in human biology at university. He became a serial entrepreneur and in 1982, founded a number of companies in Britain’s media sector. Over the past 10 years, though, he has increasingly focused on the health care sector, and has dedicated almost all of his time in the past five years to the development of Oncimmune. In this interview with BioTuesdays.com, Mr. Hamilton-Fairley discusses the company’s EarlyCDT platform technology, its lead product for the early detection of lung cancer, pipeline projects and early results from the largest National Health Service study of lung cancer screening, which is using Oncimmune’s EarlyCDT-Lung blood test.

Read More